Global epidemiology of carbapenem-resistant Pseudomonas aeruginosa
Abstract
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a common pathogen that is responsible for infections that cause high morbidity and mortality worldwide. Carbapenem resistance in P. aeruginosa may be mediated by multiple mechanisms, including changes in outer membrane permeability, efflux pumps, or production of carbapenemases. While approximately one-quarter of P. aeruginosa isolates are resistant to carbapenems worldwide, the global distribution of CRPA and carbapenemase-producing isolates varies by geographic region. The proportion of P. aeruginosa isolates that are resistant to carbapenems is particularly high in certain countries in Latin America, Eastern Europe, Southeast Asia, Africa, and the Middle East. Carbapenemase-producing CRPA isolates are rare in the USA (2%) but are more commonly encountered in other regions, with the metallo-β-lactamase (MBL) Verona integron-encoded MBL (VIM) predominating in many countries. Patients at greatest risk for infections due to CRPA include hospitalized patients, particularly those in intensive care units, residents of long-term acute-care hospitals, immunocompromised patients, and patients with cystic fibrosis. When traditional antipseudomonal agents lack activity against CRPA, novel β-lactam/β-lactamase inhibitor combinations may be effective treatment options, and cefiderocol may retain in vitro activity against MBL-producing CRPA. Continued epidemiologic monitoring and development of new antibiotics will be crucial to…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.